Virus-Induced Unfolded Protein Response Attenuates Antiviral Defenses via Phosphorylation-Dependent Degradation of the Type I Interferon Receptor

Cell Host and Microbe

Volumn 5, Issue 1, 2009, Pages 72-83

  Liu, Jianghuai ^a   HuangFu, Wei Chun ^a   Kumar, K G Suresh ^a   Qian, Juan ^a   Casey, James P ^a   Hamanaka, Robert B ^a,b   Grigoriadou, Christina ^a,b   Aldabe, Rafael ^c   Diehl, J Alan ^a,b   Fuchs, Serge Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

CELLBIO; MICROBIO; MOLIMMUNO

Indexed keywords

INTERFERON RECEPTOR; INTERFERON RECEPTOR 1; PROTEIN KINASE; PROTEIN PERK; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CONTROLLED STUDY; EMBRYONIC STEM CELL; ENDOPLASMIC RETICULUM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; MUTANT; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; UBIQUITINATION; VIRUS INFECTION; VIRUS RESISTANCE;

EIF-2 KINASE; ENDOPLASMIC RETICULUM; GENE KNOCK-IN TECHNIQUES; PROTEIN FOLDING; RECEPTOR, INTERFERON ALPHA-BETA; VIRUSES;

EID: 58249084172     PISSN: 19313128     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chom.2008.11.008     Document Type: Article

References (54)

1. Baltzis D., Qu L.K., Papadopoulou S., Blais J.D., Bell J.C., Sonenberg N., and Koromilas A.E. Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR. J. Virol. 78 (2004) 12747-12761
2. Bergmann M., Garcia-Sastre A., Carnero E., Pehamberger H., Wolff K., Palese P., and Muster T. Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. J. Virol. 74 (2000) 6203-6206
3. Biron C.A. Interferons alpha and beta as immune regulators-a new look. Immunity 14 (2001) 661-664
4. Blalock J.E., and Baron S. Mechanisms of interferon induced transfer of viral resistance between animal cells. J. Gen. Virol. 42 (1979) 363-372
5. Brassard D.L., Grace M.J., and Bordens R.W. Interferon-alpha as an immunotherapeutic protein. J. Leukoc. Biol. 71 (2002) 565-581
6. Chawla-Sarkar M., Leaman D.W., Jacobs B.S., and Borden E.C. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J. Immunol. 169 (2002) 847-855
7. Chawla-Sarkar M., Leaman D.W., Jacobs B.S., Tuthill R.J., Chatterjee-Kishore M., Stark G.R., and Borden E.C. Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (stat1). J. Interferon Cytokine Res. 22 (2002) 603-613
8. Ciccaglione A.R., Costantino A., Tritarelli E., Marcantonio C., Equestre M., Marziliano N., and Rapicetta M. Activation of endoplasmic reticulum stress response by hepatitis C virus proteins. Arch. Virol. 150 (2005) 1339-1356
9. Ciccaglione A.R., Marcantonio C., Tritarelli E., Equestre M., Vendittelli F., Costantino A., Geraci A., and Rapicetta M. Activation of the ER stress gene gadd153 by hepatitis C virus sensitizes cells to oxidant injury. Virus Res. 126 (2007) 128-138
10. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., and Naldini L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72 (1998) 8463-8471
11. Fribley A., Zeng Q., and Wang C.Y. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol. Cell. Biol. 24 (2004) 9695-9704
12. Friedman R.M., and Sonnabend J.A. Mechanism of action of interferon. Arch. Intern. Med. 126 (1970) 51-63
13. Gale Jr. M.J., Korth M.J., Tang N.M., Tan S.L., Hopkins D.A., Dever T.E., Polyak S.J., Gretch D.R., and Katze M.G. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230 (1997) 217-227
14. Gil L.H., van Olphen A.L., Mittal S.K., and Donis R.O. Modulation of PKR activity in cells infected by bovine viral diarrhea virus. Virus Res. 116 (2006) 69-77
15. Guidotti L.G., and Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19 (2001) 65-91
16. He B. Viruses, endoplasmic reticulum stress, and interferon responses. Cell Death Differ. 13 (2006) 393-403
17. Hwang S.Y., Hertzog P.J., Holland K.A., Sumarsono S.H., Tymms M.J., Hamilton J.A., Whitty G., Bertoncello I., and Kola I. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc. Natl. Acad. Sci. USA 92 (1995) 11284-11288
18. John J., McKendry R., Pellegrini S., Flavell D., Kerr I.M., and Stark G.R. Isolation and characterization of a new mutant human cell line unresponsive to alpha and beta interferons. Mol. Cell. Biol. 11 (1991) 4189-4195
19. Karp C.L., Biron C.A., and Irani D.N. Interferon beta in multiple sclerosis: is IL-12 suppression the key?. Immunol. Today 21 (2000) 24-28
20. Katze M.G., He Y., and Gale Jr. M. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2 (2002) 675-687
21. Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin. Oncol. 29 (2002) 18-26
22. Kumar K.G., Tang W., Ravindranath A.K., Clark W.A., Croze E., and Fuchs S.Y. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J. 22 (2003) 5480-5490
23. Kumar K.G., Krolewski J.J., and Fuchs S.Y. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J. Biol. Chem. 279 (2004) 46614-46620
24. Kumar K.G., Barriere H., Carbone C.J., Liu J., Swaminathan G., Xu P., Li Y., Baker D.P., Peng J., Lukacs G.L., and Fuchs S.Y. Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis. J. Cell Biol. 179 (2007) 935-950
25. Kumar K.G., Liu J., Li Y., Yu D., Thomas-Tikhonenko A., Herlyn M., and Fuchs S.Y. Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biol. Ther. 6 (2007) 1437-1441
26. Langland J.O., and Jacobs B.L. The role of the PKR-inhibitory genes, E3L and K3L, in determining vaccinia virus host range. Virology 299 (2002) 133-141
27. Liu J., Plotnikov A., Banerjee A., Suresh Kumar K.G., Ragimbeau J., Marijanovic Z., Baker D.P., Pellegrini S., and Fuchs S.Y. Ligand-independent pathway that controls stability of interferon alpha receptor. Biochem. Biophys. Res. Commun. 367 (2008) 388-393
28. Lockart Jr. R.Z. Production of an interferon by L cells infected with Western equine encephalomyelitis virus. J. Bacteriol. 85 (1963) 556-566
29. Lockart Jr. R.Z., and Horn B. Interaction of an interferon with L cells. J. Bacteriol. 85 (1963) 996-1002
30. Luquin E., Larrea E., Civeira M.P., Prieto J., and Aldabe R. HCV structural proteins interfere with interferon-alpha Jak/STAT signalling pathway. Antiviral Res. 76 (2007) 194-197
31. Maatman R., Gertsenstein M., de Meijer E., Nagy A., and Vintersten K. Aggregation of embryos and embryonic stem cells. Methods Mol. Biol. 209 (2003) 201-230
32. Malhotra J.D., and Kaufman R.J. The endoplasmic reticulum and the unfolded protein response. Semin. Cell Dev. Biol. 18 (2007) 716-731
33. Marijanovic Z., Ragimbeau J., Kumar K.G., Fuchs S.Y., and Pellegrini S. TYK2 activity promotes ligand-induced IFNAR1 proteolysis. Biochem. J. 397 (2006) 31-38
34. Muller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., and Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 264 (1994) 1918-1921
35. Nawrocki S.T., Carew J.S., Dunner Jr. K., Boise L.H., Chiao P.J., Huang P., Abbruzzese J.L., and McConkey D.J. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res. 65 (2005) 11510-11519
36. Obeng E.A., Carlson L.M., Gutman D.M., Harrington Jr. W.J., Lee K.P., and Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107 (2006) 4907-4916
37. Pestka S. The human interferon alpha species and receptors. Biopolymers 55 (2000) 254-287
38. Pfeffer L.M., and Colamonici O.R. Transmembrane signalling by interferon-alpha. Pharmacol. Ther. 52 (1991) 149-157
39. Ron D., and Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8 (2007) 519-529
40. Schreiber R.D., and Farrar M.A. The biology and biochemistry of interferon-gamma and its receptor. Gastroenterol. Jpn. 28 Suppl 4 (1993) 88-94
41. Schroder M., and Kaufman R.J. Divergent roles of IRE1alpha and PERK in the unfolded protein response. Curr. Mol. Med. 6 (2006) 5-36
42. Sharma S., tenOever B.R., Grandvaux N., Zhou G.P., Lin R., and Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 300 (2003) 1148-1151
43. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu. Rev. Biochem. 67 (1998) 227-264
44. Takaoka A., Mitani Y., Suemori H., Sato M., Yokochi T., Noguchi S., Tanaka N., and Taniguchi T. Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science 288 (2000) 2357-2360
45. Tardif K.D., Waris G., and Siddiqui A. Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol. 13 (2005) 159-163
46. Tompkins W.A. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J. Interferon Cytokine Res. 19 (1999) 817-828
47. Velazquez L., Fellous M., Stark G.R., and Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 70 (1992) 313-322
48. Wang T., and Weinman S.A. Causes and consequences of mitochondrial reactive oxygen species generation in hepatitis C. J. Gastroenterol. Hepatol. 21 Suppl 3 (2006) S34-S37
49. Waris G., Tardif K.D., and Siddiqui A. Endoplasmic reticulum (ER) stress: hepatitis C virus induces an ER-nucleus signal transduction pathway and activates NF-kappaB and STAT-3. Biochem. Pharmacol. 64 (2002) 1425-1430
50. Welihinda A.A., Tirasophon W., and Kaufman R.J. The cellular response to protein misfolding in the endoplasmic reticulum. Gene Expr. 7 (1999) 293-300
51. Wu J.Z. Internally located signal peptides direct hepatitis C virus polyprotein processing in the ER membrane. IUBMB Life 51 (2001) 19-23
52. Yamaguchi Y., Larkin D., Lara-Lemus R., Ramos-Castañeda J., Liu M., and Arvan P. ER chaperone regulation, and survival of cells compensating for deficiency in the ER stress response kinase, PERK. J. Biol. Chem. 283 (2008) 17020-17029
53. Zhang P., McGrath B., Li S., Frank A., Zambito F., Reinert J., Gannon M., Ma K., McNaughton K., and Cavener D.R. The PERK eukaryotic initiation factor 2 alpha kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. Mol. Cell. Biol. 22 (2002) 3864-3874
54. Zheng Y., Gao B., Ye L., Kong L., Jing W., Yang X., and Wu Z. Hepatitis C virus non-structural protein NS4B can modulate an unfolded protein response. J. Microbiol. 43 (2005) 529-536